Please add the following claims:

21. (New) The method of claim 6, said amount of an interferon being greater than about 20 x 10^6 IU of interferon for a 70 kg human.

22. (New) The method of claim 6, in which the effective dose of interferon is administered in a single dose.

23. (New) The method of claim 6, in which the effective dose of interferon is administered in a plurality of smaller doses over a period of time sufficient to elicit a response equivalent to that of a single dose.

24. (New) The method of claim 6, in which an effective dose of interferon is administered continuously over a period of time sufficient to elicit a response equivalent to that of a single dose.

25. (New) The method of claim 6, wherein the interferon comprises a Type I interferon.

26. (New) The method of claim 25, wherein the interferon is selected from the group consisting of IFN-α, IFN-β, IFN-ω, consensus IFN, and mixtures thereof.

27. (New) The method of claim 26, wherein the IFN-α comprises recombinant IFN-α.

28. (New) The method of claim 6, wherein the interferon comprises a Type II interferon.

29. (New) The method of claim 28, wherein the Type II interferon comprises IFN-γ.

30. (New) The method of claim 6, wherein the dose of interferon is ~~from about~~ greater than 20 x 10^6 IU to about 1000 x 10^6 IU of interferon.

31. (New) The method of claim 6, wherein the dose of interferon is ~~from about~~ greater than 20 x 10^6 IU to about 500 x 10^6 IU of interferon.

32. (New) The method of claim 6, wherein the dose of interferon is from about 50 x 10^6 IU to about 500 x 10^6 IU of interferon.

33. (New) The method of claim 6, wherein the neoplastic ~~disease~~ condition is selected from the group consisting of renal cell carcinoma, bladder cancer, cervical cancer, malignant melanoma, multiple myeloma, Kaposi's sarcoma, hairy cell leukemia, non-Hodgkin's lymphoma, chronic myeloid leukemia, nasopharyngeal carcinoma, breast cancer, large bowel (colon) cancer, uterine cancer, head and neck cancers, glioblastoma, cutaneous T-cell lymphoma, basal cell carcinoma, brain tumors, and lung cancer.

REMARKS

New Claims 21-32 depend from Claim 6 and contain limitations previously found in prior claims 1, 3-5, 7-12, and 14-16. Claim 33 further specifies neoplastic conditions for which the interferon is either approved for use or currently involved in efficacy studies. Support for Claim 33 can be found on pages 6-7.

Rejection under 35 USC §103 of claims 17-20

Claims 17-20 stand rejected under 35 USC §103(a) as being unpatentable over Samo et al. Samo allegedly teaches a dose of 40 x 10^6 units of interferon and, thus, provides the motivation to make the claimed composition. Applicants respectfully disagree.

The instant invention is directed to the oromucosal administration of an ultra-high dose for interferon treatment, free of adverse reactions, of a neoplastic disease. First, , Samo et al., by their own admission, administer "two relatively small doses" of interferon. See Abstract. Further, Applicants note